Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
13.23
+0.15 (1.15%)
At close: Jun 25, 2026, 4:00 PM EDT
13.26
+0.03 (0.23%)
After-hours: Jun 25, 2026, 7:57 PM EDT
Zevra Therapeutics Employees
Zevra Therapeutics had 61 employees as of December 31, 2025. The number of employees increased by 2 or 3.39% compared to the previous year.
Employees
61
Change (1Y)
2
Growth (1Y)
3.39%
Revenue / Employee
$2,004,738
Profits / Employee
$1,918,049
Market Cap
782.09M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 61 | 2 | 3.39% | 61 | 0 |
| Dec 31, 2024 | 59 | -10 | -14.49% | 59 | 0 |
| Dec 31, 2023 | 69 | 33 | 91.67% | 65 | 4 |
| Dec 31, 2022 | 36 | 12 | 50.00% | 32 | 4 |
| Dec 31, 2021 | 24 | 2 | 9.09% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Omeros | 175 |
| Allogene Therapeutics | 152 |
| Aura Biosciences | 113 |
| Inventiva | 77 |
| Vor Biopharma | 76 |
| CytomX Therapeutics | 69 |
| Oculis Holding AG | 60 |
| Climb Bio | 29 |
ZVRA News
- 2 days ago - Zevra publishes Miplyffa data in Molecular Genetics, Metabolism Reports - TheFly
- 2 days ago - Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) - GlobeNewsWire
- 14 days ago - Zevra Therapeutics chief medical officer to step down - TheFly
- 14 days ago - Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition - GlobeNewsWire
- 15 days ago - Zevra Therapeutics price target raised to $35 from $25 at Maxim - TheFly
- 15 days ago - Zevra Therapeutics price target raised to $29 from $25 at Guggenheim - TheFly
- 16 days ago - Zevra Therapeutics price target raised to $27 from $23 at BTIG - TheFly
- 16 days ago - Zevra Therapeutics price target raised to $29 from $24 at Canaccord - TheFly